Sebaceous carcinoma: Controversies and their evidence for clinical practice Review


Authors: Kibbi, N.; Worley, B.; Owen, J. L.; Kelm, R. C.; Bichakjian, C. K.; Chandra, S.; Demirci, H.; Kim, J.; Nehal, K. S.; Thomas, J. R.; Poon, E.; Alam, M.
Review Title: Sebaceous carcinoma: Controversies and their evidence for clinical practice
Abstract: Sebaceous carcinoma (SC) is a potentially aggressive malignancy of periocular or extraocular skin. It arises sporadically or is associated with Muir–Torre syndrome (MTS). Here, we review three controversial clinical conundra related to the diagnosis and treatment of SC and offer evidence-based recommendations. First, following a diagnosis of SC, deciding which patients to screen for MTS can be challenging. The Mayo MTS Risk Score is a clinical score that incorporates the key cutaneous findings in MTS but relies heavily on personal and family history that may not be available at the time of SC diagnosis, especially in young patients. Young patients, who have extraocular SC and are suspected to have MTS though do not meet criteria by Mayo MTS Risk Score, should have their tumors tested using immunohistochemistry for mismatch repair proteins. Second, sentinel lymph node biopsy (SLNB) is used in periocular SC to evaluate nodal disease. Patient selection is critical for SLNB. Periocular SC stage ≥ T2c (by American Joint Commission on Cancer, 8th edition) may be considered for SLNB given positivity rates over fifteen percent in expert hands. Lastly, treatment of metastatic SC is an area of active investigation. When possible, tumor profiling may be used to select targeted agents. Future research into these three key questions is needed. © 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
Keywords: cancer chemotherapy; review; systemic therapy; treatment; lymph node metastasis; antineoplastic agent; cancer diagnosis; sentinel lymph node biopsy; cancer immunotherapy; evidence based practice; cancer therapy; gene therapy; genetic screening; management; lynch syndrome; sebaceous carcinoma; molecularly targeted therapy; human; priority journal; muir torre syndrome; cutaneous oncology; antineoplastic monoclonal antibody; muir–torre syndrome
Journal Title: Archives of Dermatological Research
Volume: 312
Issue: 1
ISSN: 0340-3696
Publisher: Springer  
Date Published: 2020-01-01
Start Page: 25
End Page: 31
Language: English
DOI: 10.1007/s00403-019-01971-4
PUBMED: 31471636
PROVIDER: scopus
DOI/URL:
Notes: Review -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Kishwer S Nehal
    278 Nehal